Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.70 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.70 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.70 |
| ▸ | PIM1 | P11309 | 1/20 | 0.70 |
| ▸ | PRKACA | P17612 | 1/20 | 0.70 |
| ▸ | CDK7 | P50613 | 1/20 | 0.70 |
| ▸ | CDK9 | P50750 | 1/20 | 0.70 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.70 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.70 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.60 |
| ▸ | MAPK10 | P53779 | 16/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 14/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5563903 | 0.88 | CDC7 (0.55) | CDC7ROCK2MAP4K4PIM1PRKACA | |
| SCHEMBL2029526 | 0.86 | PTK2 (0.58) | CDC7ROCK2MAP4K4PIM1PRKACA | |
| SCHEMBL26970244 | 0.85 | CDC7 (0.52) | CDC7ROCK2MAP4K4PIM1PRKACA | |
| SCHEMBL29525943 | 0.85 | CDC7 (0.52) | CDC7ROCK2MAP4K4PIM1PRKACA | |
| SCHEMBL25234152 | 0.85 | CDC7 (0.53) | CDC7ROCK2MAP4K4PIM1PRKACA | |
| SCHEMBL30646195 | 0.85 | CDC7 (0.53) | CDC7ROCK2MAP4K4PIM1PRKACA | |
| SCHEMBL12813038 | 0.85 | CDC7 (0.52) | CDC7ROCK2MAP4K4PIM1PRKACA | |
| SCHEMBL1203456 | 0.84 | MAPK8 (0.61) | CDC7ROCK2MAP4K4PIM1PRKACA | |
| SCHEMBL12879785 | 0.83 | CDC7 (0.78) | CDC7ROCK2MAP4K4PIM1PRKACA | |
| SCHEMBL1202555 | 0.83 | MAPK10 (0.68) | CDC7ROCK2MAP4K4PIM1PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884098-B2 | 2-{[5-Fluoro-2-({3-[2-(4-morpholinyl)ethyl]phenyl}amino)-4-pyrimidinyl]amino}-N-(2-hydroxyethyl)benzamide, useful in the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-02-08 | — | — | US | disclosed |
| US-20100016318-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-21 | — | — | US | disclosed |
| US-7625903-B2 | Anticancer agent; N-(1-methylethyl)-2-[(5-methyl-2-{[3-(4-methyl-2-oxo-1-piperazinyl)phenyl]amino}-4-pyrimidinyl)amino]benzamide | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-01 | — | — | US | disclosed |
| EP-2121637-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | Smithkline Beecham Corporation (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080182852-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | GLAXOSMITHKLINE LLC | 2008-07-31 | — | — | US | disclosed |
| WO-2008092049-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182852-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | AURKA, AURKC, AURKB | CDC7 53/4885ROCK2 130/4885MAP4K4 188/4885 |
| US-20100016318-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | AURKA, AURKC, AURKB | CDC7 57/4885ROCK2 101/4885MAP4K4 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.